{
    "clinical_study": {
        "@rank": "142824", 
        "arm_group": {
            "arm_group_label": "EGFR positive arm", 
            "arm_group_type": "Experimental", 
            "description": "Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)"
        }, 
        "brief_summary": {
            "textblock": "To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer\n      harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR\n      method."
        }, 
        "brief_title": "Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "EGFR Mutation Positive Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Histologically confirmed NSCLC 2. Aged of or older than 20 years 3. ECOG\n             performance status 0-2 4. Adequate hematological, renal, hepatic function 5. Patients\n             with tumors harboring EGFR mutation (del 19 or L858R mutation) 6. Patient who are\n             about to be treated with EGFR TKI (gefitinib, erlotinib or other EGFR TKI) 7. At\n             least more than one measurable disease 8. Informed consent\n\n        Exclusion Criteria:\n\n          -  1. Active infection 2. Active bleeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776684", 
            "org_study_id": "2011-10-054"
        }, 
        "intervention": {
            "arm_group_label": "EGFR positive arm", 
            "intervention_name": "EGFR TKIs (gefitinib, erlotinib, afatinib, et al)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gefitinib", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 25, 2013", 
        "location": {
            "contact": {
                "email": "silkahn@skku.edu", 
                "last_name": "Myung-Ju Ahn, M.D., Ph.D."
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Detection of Resistance Genes From Serially Collected Plasma DNA in Non-small Cell Lung Cancer Patients Harboring EGFR Activating Mutation Who Are Being Treated With EGFR TKIs", 
        "overall_contact": {
            "email": "silkahn@skku.edu", 
            "last_name": "Myung-Ju Ahn, M.D., Ph.D."
        }, 
        "overall_contact_backup": {
            "email": "tntntn3@gmail.com", 
            "last_name": "Jong-Mu Sun, M.D., Ph.D."
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the efficiency of castPCR method for detection of resistance genes, especially, T790M mutation from serially collected plasma DNA in non-small cell lung cancer patients harboring EGFR activating mutation who are being treated with EGFR TKIs", 
            "measure": "detection of resistant gene", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776684"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Myung-Ju Ahn", 
            "investigator_title": "M.D., Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}